The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response

The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response

(1) Background: The first line of treatment for recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) has recently evolved with the approval of immunotherapies that target the anti-PD-1 immune checkpoint. However, only about 20% of the patients display a long-lasting objective tumor res...

Full description

Bibliographic Details
Main Authors: Justine De Azevedo, Jana Mourtada, Cyril Bour, Véronique Devignot, Philippe Schultz, Christian Borel, Erwan Pencreach, Georg Mellitzer, Christian Gaiddon, Alain C. Jung
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cells
Subjects:
head and neck squamous cell carcinoma
cetuximab
cisplatin
apoptosis
immunogenic cell death
Online Access:https://www.mdpi.com/2073-4409/11/18/2866

Internet

https://www.mdpi.com/2073-4409/11/18/2866

Similar Items